REFERENCES
1. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: Not your grandmother’s cancer. Cancer . 2016 Sep 15;122(18):2787-98.
2. Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on Conservative Management of Endometrial Cancer. J Minim Invasive Gynecol . 2018 Feb;25(2):308-13.
3. Taylan E, Oktay K. Fertility preservation in gynecologic cancers.Gynecologic oncology . 2019 Dec;155(3):522-9.
4. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer . 2013 Mar;49(4):868-74.
5. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol . 2017 Jan;28(1):e2.
6. Wang Y, Yang JX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience. Cancer Manag Res . 2018;10:6803-13.
7. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.Gynecol Oncol . 2012 May;125(2):477-82.
8. Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol . 2019 Apr;153(1):55-62.
9. Mitsuhashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol . 2019 Nov;30(6):e90.
10. Royal College of Obstetricians and Gynaecologists; British Society for Gynaecological Endoscopy. Management of endometrial hyperplasia: Green-top Guideline No. 67. RCOG/BSGE Joint Guideline February 2016. London: Royal College of Obstetricians and Gynaecologists; 2016.
11. Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ, Sebastianelli A. Guideline No. 390-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can . 2019 Dec;41(12):1789-800.
12. Mandelbaum RS, Ciccone MA, Nusbaum DJ, Khoshchehreh M, Purswani H, Morocco EB, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol . 2020 Jul;223(1):103 e1- e13.
13. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Dec;203(6):547 e1-10.
14. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, et al. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol . 2018 Jan;131(1):109-16.
15. Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ, 3rd. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. Gynecol Oncol . 2016 Feb;140(2):234-8.
16. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ . 2012 May 10;344:e2990.
17. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod . 2010 May;25(5):1158-64.
18. Jareid M, Thalabard JC, Aarflot M, Bovelstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol . 2018 Apr;149(1):127-32.
19. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, et al. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 Feb;224(2):191 e1- e15.
20. Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG . 2010 Jun;117(7):879-84.
21. Kim MK, Seong SJ, Kim YS, Song T, Kim ML, Yoon BS, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol . 2013 Oct;209(4):358 e1-4.
22. Hwang JY, Kim DH, Bae HS, Kim ML, Jung YW, Yun BS, et al. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer. Int J Gynecol Cancer . 2017 May;27(4):738-42.
23. Zaino R, Carinelli SG, Ellenson LH, Eng C, Katabuchi H, Konishi I, et al. Tumours of the uterine corpus: Epithelial tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO classificationof tumours of female reproductive organs, 4th ed. Lyon, France: IARC; 2014.
24. Zhou S, Xu Z, Yang B, Guan J, Shan W, Shi Y, et al. Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.J Gynecol Oncol . 2021 Jul;32(4):e57.
25. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in C. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002 Mar;15(1):83-96.
26. Yang Z, Ding X, Liu J, Duan P, Si L, Wan B, et al. Associations between anthropometric parameters and lipid profiles in Chinese individuals with age >/=40 years and BMI <28kg/m2. PLoS One . 2017;12(6):e0178343.
27. Shan W, Ning C, Luo X, Zhou Q, Gu C, Zhang Z, et al. Hyperinsulinemia is associated with endometrial hyperplasia and disordered proliferative endometrium: a prospective cross-sectional study. Gynecol Oncol . 2014 Mar;132(3):606-10.
28. Yang B, Xie L, Zhang H, Zhu Q, Du Y, Luo X, et al. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients. J Gynecol Onco l. 2018 May;29(3):e35.
29. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA . 2001 May 16;285(19):2486-97.
30. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.Lancet . 2005 Apr 16-22;365(9468):1415-28.
31. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas . 2007 Jun 20;57(2):210-3.
32. Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. Int J Gynecol Cancer . 2015 Jul;25(6):1010-4.
33. Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.Int J Gynaecol Obstet . 2016 Jan;132(1):34-8.
34. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg . 2012;10(1):28-55.
35. Shoupe D, Mishell DR Jr. The handbook of contraception: A guide for practical management. 2nd ed. 2016. In the series: Current clinical practice. Skolink NS, series editor. Totowa, NJ: Humana Press Inc.; 2016.
36. Apgar BS, Greenberg G. Using progestins in clinical practice.Am Fam Physician. 2000 Oct 15;62(8):1839-46, 49-50.
37. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev . 2020 Sep 6;9:CD012658.
38. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. J Clin Oncol.2016 Dec 10;34(35):4225-30.
39. MacKintosh ML, Derbyshire AE, McVey RJ, Bolton J, Nickkho-Amiry M, Higgins CL, et al. The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. Int J Cancer . 2019 Feb 1;144(3):641-50.
40. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) . 1982 Dec;17(6):529-36.